IP Verse

Methods And Materials For Assessing Homologous Recombination Deficiency - EP3180447

The patent EP3180447 was granted to Myriad Genetics on Mar 11, 2020. The application was originally filed on Aug 17, 2015 under application number EP15757372A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3180447

MYRIAD GENETICS
Application Number
EP15757372A
Filing Date
Aug 17, 2015
Status
Opposition Rejected
Sep 8, 2023
Publication Date
Mar 11, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SIEMENS HEALTHCAREDec 10, 2020LIERADMISSIBLE

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
EXAMINATIONEP2981624
INTERNATIONAL-SEARCH-REPORTWO2012027224
INTERNATIONAL-SEARCH-REPORTWO2013130347
OPPOSITIONWO2011160063
OPPOSITIONWO2012027224
OPPOSITIONWO2013130347

Non-Patent Literature (NPL) Citations (13) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- Anonymous, "Myriad's HRD Test Significantly Predicts Response to Cisplatin Treatment in Patients With Triple Negative Breast Cancer in Second Research Study", (20131214), URL: http://files.shareholder.com/downloads/MYGN/3039924177x0x713818/74F0EC3E-B337-4724-A51B-63BA3BD75A08/MYGN_News_2013_12_14_General.pdf, (20161019), XP055312045
EXAMINATION- HODGSON DARREN R ET AL, "Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond theBRCAgenes", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 119, no. 11, doi:10.1038/S41416-018-0274-8, ISSN 0007-0920, (20181024), pages 1401 - 1409, (20181024), XP036647665
EXAMINATION- EUAN A. STRONACH ET AL, "Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy", MOLECULAR CANCER RESEARCH, US, (20180503), vol. 16, no. 7, doi:10.1158/1541-7786.MCR-18-0034, ISSN 1541-7786, pages 1103 - 1111, XP055539341
INTERNATIONAL-SEARCH-REPORT- T. POPOVA ET AL, "Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation", CANCER RESEARCH, (20120829), doi:10.1158/0008-5472.CAN-12-1470, ISSN 0008-5472, XP055039519 [A] 1-36
OPPOSITION- Anonymous, "Myriad Presents Data on BRACAnalysis CDx and HRD at 2014 ASCO Meeting", Myriad Press release, (20140530), pages 1 - 3, XP055802944
OPPOSITION- Anonymous, "Myriad's HRD Test Significantly Predicts Response to Cisplatin Treatment in Patients With Triple Negative Breast Cancer in Second Research Study", Myriad, (20131214), XP055312045
OPPOSITION- Isakoff Steven J, Et Al, "Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009", Journal of Clinical Oncology, (20140520), vol. 32, no. 15 suppl, pages 1 - 4, XP055802939
OPPOSITION- Mayer Erica L, Et Al, "TBCRC030: A randomized, phase 11 study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)- Evaluating the homologous recombination deficiency (HRD) biomarker", Journal of Clinical Oncology, (20140520), vol. 32, no. 15 suppl, pages 1 - 4, XP055802941
OPPOSITION- Timms K M, Et Al, "Abstract P 6-05-10: Association between BRCA1/2 status and DNA-based assays for homologous recombination deficiency in breast cancer", Cancer Research. Poster Session Abstracts, (20131201), vol. 73, no. 24 suppl, pages 1 - 2, XP055802934
OPPOSITION- ABKEVICH, A. et al., "Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer", British Journal of Cancer, (20121009), vol. 107, doi:10.1038/bjc.2012.451, pages 1776 - 1782, XP055085758
OPPOSITION- POPOVA, T. et al., "Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation", Cancer Res, vol. 72, no. 21, doi:10.1158/0008-5472.CAN-12-1470, (20120829), pages 5454 - 5462, XP055341888
OPPOSITION- BIRBAK, N.J. et al., "Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents", Cancer Discovery, (20120322), vol. 2, doi:10.1158/2159-8290.CD-11-0206, pages 366 - 375, XP055162779
OPPOSITION- WATKINS,J.A. et al., "Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers", Breast Cancer Research, (20140603), vol. 16, doi:10.1186/bcr3670, page 211, XP021205594

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents